BoB@JPM: Ron Cooper, enGene

What It Covers

Ron Cooper, CEO of enGene, traces his path from 30 years at Bristol Myers Squibb through building and selling Albireo Pharma to Ipsen for $1.2B, to leading enGene's nonviral gene therapy for non-muscle invasive bladder cancer, covering biotech scaling, fundraising, manufacturing strategy, and the 2025 industry outlook.

Key Questions Answered

• •Biotech Scaling Framework: Keep three cycles synchronized at all times: science/development, financing, and human capital. When one cycle outpaces the others, value destruction follows. At Albireo, the development cycle was ahead while financing and talent lagged, making those the first priorities. Misalignment forces compromised scientific decisions or excessive cash burn before revenue exists.
• •Non-Dilutive Capital Strategy: Of over $1B raised across his career, roughly half came from non-dilutive sources. Early-stage biotech CEOs should pursue creative financing structures beyond equity rounds — including reverse mergers, partnerships, and grants. At Albireo, seven financial transactions in two years kept the company alive, with six being deal structures Cooper had never previously executed.
• •M&A Readiness — Five Dimensions: Potential acquirers evaluate far more than clinical data. Companies should proactively update strategic partners across five areas: patent position, manufacturing status, preclinical data, business model, and clinical results. Albireo attracted four simultaneous bidders partly because all parties were continuously informed, enabling fast, competitive deal execution rather than slow due diligence catch-up.
• •CMC Investment Timing: Chemistry, manufacturing, and controls spending should begin earlier than most biotechs prioritize, and often exceeds clinical spend in early stages. Most recent FDA complete response letters cite manufacturing failures, not clinical ones. enGene already completed FDA validation batches (PPQ) and participates in the FDA's CDRP pilot program — one of only nine companies selected — reducing CRL risk substantially.
• •Community Urology Market Dynamics: Approximately 80% of non-muscle invasive bladder cancer patients receive treatment in community urology settings, not major academic centers. Community urologists weight three factors when selecting therapies: efficacy, tolerability, and practice-flow compatibility. enGene's EG-70 requires only refrigeration, water mixing, and standard catheter instillation — no viral handling protocols, bleaching, or specialized equipment — fitting directly into existing practice workflows.